Posters

EGM as a Tool for Detection of Gene Fusions and TP53 Deletions in Genomic Analysis

Nabsys OhmX Platform

Understanding the genetic drivers of cancer requires tools that deliver both precision and scalability. This study demonstrates how the OhmX™ Platform—powered by electronic genome mapping (EGM)—detects clinically significant gene fusions (PML::RARA, BCR::ABL1, RUNX1::RUNX1T1) and TP53 deletions with high resolution and accuracy.

By leveraging dense, sequence-specific tagging and solid-state nanochannel detection, EGM provides confident identification of structural variants that often elude traditional sequencing and cytogenetic techniques. The platform’s ability to confirm variants across diverse leukemia cell models underscores its potential for integration into diagnostic and translational research workflows.

Explore how EGM delivers scalable, cost-effective genomic insights that drive progress toward precision oncology.

Download PDF

Download Now

Please complete the form to download this poster.
EGM as a Tool for Detection of Gene Fusions and TP53 Deletions in Genomic Analysis
Share This

Research Areas & Applications

No items found.
Cancer Research
Gain deeper insights and drive breakthroughs in cancer research with the OhmX™ Platform,  powered by electronic genome mapping (EGM) and expertly engineered to unravel the complexities of structural variants (SVs) in cancer genomes.
Orthogonal Validation of NGS and LRS
Gain confidence in your genomic discoveries from NGS and long-read sequencing (LRS) platforms with a low-cost solution to verify, clarify, and identify structural variant (SV) calls.
Rare Disease
Unravel complexities and gain critical insights with the OhmX™ Platform, designed to help you push the boundaries of rare disease research.
Cell and Gene Therapy
EGM provides clarity to genomic integrity where other tools can’t.

Ask an expert how you can get the  most with the OhmX platform.

Get in TouchView Resources